The frequency of BRAF mutation in very small papillary thyroid carcinomas

Korean Journal of Pathology

Volumn 44, Issue 3, 2010, Pages 308-314

  Kim, Taeeun ^a   Roh, Ji Hyun ^a   Park, Hee Jung ^a   Kwon, Jee Eun ^a   Kang, So Young ^a   Choi, Yoon La ^a   Oh, Young Lyun ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

BRAF; Carcinoma; Papillary; Thyroid gland

Indexed keywords

EID: 77957335491     PISSN: 17381843     EISSN: None     Source Type: Journal    
DOI: 10.4132/KoreanJPathol.2010.44.3.308     Document Type: Article

References (35)

1. Ministry for Health, Welfare and Family Affairs. Annual report of cancer incidence (2007), cancer prevalence (2007) and survival (1993-2007) in Korea. Seoul: Ministry for Health, Welfare and Family Affairs, 2009.
2. Thyroid cancer: incidence and histological pattern in Korea. Goyang: National Cancer Information Center; 2009 [cited 2010 May 10]. Available from: http://www.cancer.go.kr/cms/cancer/cancer_is/04/1191182_1753.html.
3. Bramley MD, Harrison BJ. Papillary microcarcinoma of the thyroid gland. Br J Surg 1996; 83: 1674-83.
4. Ito Y, Uruno T, Nakano K, et al. An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. Thyroid 2003; 13: 381-7.
5. Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev 2005; 31: 423-38.
6. Küçük NO, Tari P, Tokmak E, Aras G. Treatment for microcarcinoma of the thyroid: clinical experience. Clin Nucl Med 2007; 32: 279-81.
7. Roti E, Rossi R, Trasforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006; 91: 2171-8.
8. Besic N, Pilko G, Petric R, Hocevar M, Zgajnar J. Papillary thyroid microcarcinoma: prognostic factors and treatment. J Surg Oncol 2008; 97: 221-5.
9. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-54.
10. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005; 12: 245-62.
11. Cahill S, Smyth P, Denning K, et al. Effect of BRAFV600E mutation on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 2007; 6: 21.
12. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004; 45: 818-21.
13. Kwak JY, Kim EK, Chung WY, Moon HJ, Kim MJ, Choi JR. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009; 253: 854-60.
14. Park YJ, Kim YA, Lee YJ, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010; 32: 38-45.
15. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC cancer staging manual. 7th ed. New York: Springer-Verlag, 2010.
16. Bongarzone I, Vigneri P, Mariani L, Collini P, Pilotti S, Pierotti MA. RET/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features. Clin Cancer Res 1998; 4: 223-8.
17. Soares P, Fonseca E, Wynford-Thomas D, Sobrinho-Simões M. Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms? J Pathol 1998; 185: 71-8.
18. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003; 63: 1454-7.
19. Soares P, Trovisco V, Rocha AS, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003; 22: 4578-80.
20. Adeniran AJ, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006; 30: 216-22.
21. Mayr D, Hirschmann A, Löhrs U, Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006; 103: 883-7.
22. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002; 62: 6997-7000.
23. Goldenberg D, Rosenbaum E, Argani P, et al. The V599E BRAF mutation is uncommon in biliary tract cancers. Mod Pathol 2004; 17: 1386-91.
24. Rha SY, Lee JC, Kwon KH, et al. The relationship between the BRAF mutations in thyroid papillary carcinomas and the prognostic factors. J Korean Soc Endocrinol 2005; 20: 224-9.
25. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005; 63: 588-93.
26. Kim KH, Suh KS, Kang DW, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 2005; 55: 540-5.
27. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol (Oxf) 2006; 65: 364-8.
28. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006; 107: 1831-8.
29. Min HS, Choe G, Cho NY, Kang GH, Park SH, Park SY. Immunohistochemical and molecular characteristics of follicular patterned thyroid nodules with incomplete nuclear features of papillary thyroid carcinoma. Korean J Pathol 2009; 43: 495-502.
30. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009; 19: 137-41.
31. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003; 88: 5399-404.
32. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-7.
33. Puxeddu E, Moretti S, Elisei R, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004; 89: 2414-20.
34. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol 2009; 16: 240-5.
35. Ugolini C, Giannini R, Lupi C, et al. Presence of BRAF V600E in very early stages of papillary thyroid carcinoma. Thyroid 2007; 17: 381-8.